Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
4
Vale SA
VALE
5
KB Home
KBH
US Stock MarketDetailed Quotes
NAUT Nautilus Biotechnology
- 1.710
- -0.010-0.58%
Close Feb 14 16:00 ET
- 1.670
- -0.040-2.34%
Post 20:01 ET
214.71MMarket Cap-3.05P/E (TTM)
1.760High1.690Low39.87KVolume1.760Open1.720Pre Close68.74KTurnover0.09%Turnover RatioLossP/E (Static)125.56MShares3.09052wk High0.96P/B78.87MFloat Cap1.56052wk Low--Dividend TTM46.12MShs Float25.886Historical High--Div YieldTTM4.07%Amplitude1.500Historical Low1.724Avg Price1Lot Size
About Nautilus Biotechnology Company
Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Company Profile
SymbolNAUT
Company NameNautilus Biotechnology
Listing DateAug 7, 2020
Issue Price10.00
Founded2016
CEOMr. Sujal M. Patel
MarketNASDAQ
Employees167
Fiscal Year Ends12-31
Address2701 Eastlake Avenue East
CitySeattle
ProvinceWashington
CountryUnited States of America
Zip Code98102
Phone1-206-333-2001
Websitehttp://www.nautilus.bio
Company Executives
- Name
- Position
- Salary
- Sujal M. Patel
- Chief Executive Officer, President, Secretary and Director
- 1.89M
- Anna Mowry
- Chief Financial Officer, Principal Accounting Officer and Treasurer
- 781.52K
- Gwen E. Weld
- Chief People Officer
- --
- Nick Nelson
- Chief Business Officer and Senior Vice President, Business Development
- --
- Dr. Subra Sankar
- Senior Vice President, Product Development
- --
- Mary E. Godwin
- Senior Vice President, Operations
- --
- Matthew L. Posard
- Chairman of the Board
- 246.98K
- Dr. Parag Mallick, PhD
- Chief Scientist and Director
- 1.02M
- Farzad Nazem
- Independent Director
- 189.98K
- Michael Altman, C.F.A.
- Independent Director
- 189.98K
- Dr. Vijay Pande, PhD
- Independent Director
- 187.98K
- Matthew S McIlwain
- Independent Director
- 202.98K
- Dr. Karen Akinsanya, PhD
- Independent Director
- 187.98K
- Melissa B. Epperly
- Independent Director
- 202.98K
- Matthew Murphy
- General Counsel
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now